WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Slate Bio | January 20, 2021
Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...
Micreos | September 22, 2020
Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...
openPR.com | April 13, 2020
Advance Market Analytics released the research report of Global Coronavirus Testing Kits Market, offers a detailed overview of the factors influencing the global business scope. Global Coronavirus Testing Kits Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Global Coronavirus Testing Kits. This Report covers the emerging player's...
Cellect Biotechnology | August 10, 2020
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension."This is a pivotal event for Cellect and perhaps one of the most crucial developments for us&nb...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE